Study	Events	Total	Proportion	95%–CI
industry = 0				
Gangadhar2011Two	0	34	0.000	[0.000; 0.103]
Jonasch2010Upfront	10	40	0.250	[0.127; 0.412]
Tagawa2011Phase	4	14	0.286	[0.084; 0.581]
Gridelli2011Sorafenib	5	60	0.083	[0.028; 0.184]
Richly2006Results	1	31	0.032	[0.001; 0.167]
Isaacs2011Phase	1	35	0.029	[0.001; 0.149]
Desar2010Phase	0	14	0.000	[0.000; 0.232]
Abou2011Pr	1	14	0.071	[0.002; 0.339]
Del2010Sorafenib	5	50	0.100	[0.033; 0.218]
Schultheis2012Phase	3	12	0.250	[0.055; 0.572]
Yang2012Cryotherapy	18	104	0.173	[0.106; 0.260]
Adjei2007Phase	1	31	0.032	[0.001; 0.167]
Davies2012Phase	0	25	0.000	[0.000; 0.137]
Duran2007Phase	3	15	0.200	[0.043; 0.481]
Escudier2007Phase	1	13	0.077	[0.002; 0.360]
Flaherty2008Phase	10	39	0.256	[0.130; 0.421]
Hong2009Phase	3	43	0.070	[0.015; 0.191]
Margolin2012Randomized	4	102	0.039	[0.011; 0.097]
Vaishampayan2010Safety	2	23	0.087	[0.011; 0.280]
Kupsch2005Results	2	32	0.062	[0.008; 0.208]
Welch2010Sorafenib	2	43	0.047	[0.006; 0.158]
El2012Randomized	1	37	0.027	[0.001; 0.142]
Kim2012Phase	10	16	0.625	[0.354; 0.848]
Kindler2012Gemcitabine	0	17	0.000	[0.000; 0.195]
Azad2008Combination	7	37	0.189	[0.080; 0.352]
Baselga2012Sorafenib	44	115	0.383	[0.294; 0.478]
Gollob2007Phase	13	40	0.325	[0.186; 0.491]
Ryan2007Sorafenib	12	62	0.194	[0.104; 0.314]
Sun2010Phase	18	44	0.409	[0.263; 0.568]
Hsu2010Phase	4	53	0.075	[0.021; 0.182]
Park2012Phase	22	50	0.440	[0.300; 0.587]
Reardon2011Effect	1	32	0.031	[0.001; 0.162]
Bellmunt2010Activity	20	40	0.500	[0.338; 0.662]
Davies2011Phase	2	10	0.200	[0.025; 0.556]
Amaravadi2009Phase	23	169	0.136	[0.088; 0.197]
Cabrera2011Combination	23	41	0.561	[0.397; 0.715]
Beasley2012Phase	7	19	0.368	[0.163; 0.616]
Berruti2012Phase	0	9	0.000	[0.000; 0.336]
Bhatia2012Phase	0	24	0.000	[0.000; 0.142]
Gonccalves2012Baypan	12	52	0.231	[0.125; 0.368]
Lee2012Phase12	2	17	0.118	[0.015; 0.364]
Lee2012Phase1	1	17	0.059	[0.001; 0.287]
Mardjuadi2012Phase	13	23	0.565	[0.345; 0.768]
Nabhan2012Phase	0	10	0.000	[0.000; 0.308]
Rosen2012Safety	1	13	0.077	[0.002; 0.360]
Azad2013Phase	2	18	0.111	[0.014; 0.347]
Chan2013Phase	1	17	0.059	[0.001; 0.287]
Den2013Phase	5	18	0.278	[0.097; 0.535]
Flaherty2013Phase	84	410	0.205	[0.167; 0.247]
Galanis2013Phase	10	54	0.185	[0.093; 0.314]
Gradishar2013Double	80	119	0.672	[0.580; 0.756]
Kelley2013Temsirolimus	2	25	0.080	[0.010; 0.260]
Loconte2013Phase	2	16	0.125	[0.016; 0.383]
Martin2013Multicenter	1	36	0.028	[0.001; 0.145]
Meyer2013Phase	1	16	0.062	[0.002; 0.302]
Mina2013Phase	0	18	0.000	[0.000; 0.185]
Navid2013Phase	3	17	0.176	[0.038; 0.434]
Peereboom2013Nabtt	0	56	0.000	[0.000; 0.064]
Xue2013Phase	42	54	0.778	[0.644; 0.880]
Canter2014Phase	1	8	0.125	[0.003; 0.527]
Cardin2014Phase	0	36	0.000	[0.000; 0.097]
Chiorean2014Phase	8	27	0.296	[0.138; 0.502]
Chow2014Multicenter	7	28	0.250	[0.107; 0.449]
El2014S0941	0	34	0.000	[0.000; 0.103]
Hagihara2014Phase	5	20	0.250	[0.087; 0.491]
Mahalingam2014Phase	0	14	0.000	[0.000; 0.232]
Ooka2014Phase	1	26	0.038	[0.001; 0.196]
Schwandt2014Randomized	17	23	0.739	[0.516; 0.898]
Sharma2014Phase	8	17	0.471	[0.230; 0.722]
Eisen2011Sorafenib	13	101	0.129	[0.070; 0.210]
Random effects model		**2929**	**0.164**	**[0.128; 0.208]**
Heterogeneity: I–squared=84%, tau–squared=1.014, p<0.0001				
industry = 1				
Egberts2011Sorafenib	4	55	0.073	[0.020; 0.176]
Larkin2010Phase	1	13	0.077	[0.002; 0.360]
Procopio2011Sorafenib	18	66	0.273	[0.170; 0.396]
Harzstark2011Phase	5	20	0.250	[0.087; 0.491]
Brendel2011Pharmacokinetic	1	23	0.043	[0.001; 0.219]
Infante2012Drug	1	27	0.037	[0.001; 0.190]
Petrini2012Phase	1	39	0.026	[0.001; 0.135]
Lind2010Multicenter	14	50	0.280	[0.162; 0.425]
Siu2006Phase	2	42	0.048	[0.006; 0.162]
Awada2012Phase	3	25	0.120	[0.025; 0.312]
Mross2007Results	1	33	0.030	[0.001; 0.158]
Ramasubbaiah2011Sorafenib	2	30	0.067	[0.008; 0.221]
Galal2011Role	6	18	0.333	[0.133; 0.590]
Okamoto2010Phase	7	12	0.583	[0.277; 0.848]
Abou2010Doxorubicin	2	47	0.043	[0.005; 0.145]
Hauschild2009Results	16	134	0.119	[0.070; 0.187]
Mcdermott2008Double	12	51	0.235	[0.128; 0.375]
Pawlik2011Phase	5	56	0.089	[0.030; 0.196]
Scagliotti2010Phase	127	464	0.274	[0.234; 0.317]
Spigel2011Randomized	9	111	0.081	[0.038; 0.148]
Amato2012Phase1	6	15	0.400	[0.163; 0.677]
Beardsley2012Phase	0	14	0.000	[0.000; 0.232]
Niwakawa2012Phase	5	18	0.278	[0.097; 0.535]
Paz2012Phase	107	385	0.278	[0.234; 0.326]
Rini2012Amg	38	101	0.376	[0.282; 0.478]
Shacham2012Phase	2	38	0.053	[0.006; 0.177]
Sieghart2012Conventional	7	15	0.467	[0.213; 0.734]
Bracarda2013Could	26	101	0.257	[0.176; 0.354]
Castellano2013Sorafenib	4	41	0.098	[0.027; 0.231]
Dasari2013Phase	0	35	0.000	[0.000; 0.100]
Finn2013Phase	0	30	0.000	[0.000; 0.116]
Hainsworth2013Sorafenib	10	75	0.133	[0.066; 0.232]
Lee2013Phase	4	33	0.121	[0.034; 0.282]
Maroto2013Phase	12	36	0.333	[0.186; 0.510]
Schwartzberg2013Sorafenib	16	81	0.198	[0.117; 0.301]
Simonelli2013Phase	5	27	0.185	[0.063; 0.381]
Tabernero2013Sorafenib	45	97	0.464	[0.362; 0.568]
Zustovich2013Sorafenib	5	42	0.119	[0.040; 0.256]
Aparicio2014Phase	2	12	0.167	[0.021; 0.484]
Cascinu2014Sorafenib	2	58	0.034	[0.004; 0.119]
Chen2014Phase	22	40	0.550	[0.385; 0.707]
Ganesan2014Phase	0	38	0.000	[0.000; 0.093]
Hong2014Phase	5	17	0.294	[0.103; 0.560]
Hottinger2014Phase	2	15	0.133	[0.017; 0.405]
Krege2014Prospective	21	40	0.525	[0.361; 0.685]
Luu2014Phase	4	41	0.098	[0.027; 0.231]
Martin2014Phase	0	11	0.000	[0.000; 0.285]
Monk2014Phase	3	17	0.176	[0.038; 0.434]
Naqi2014Efficacy	2	18	0.111	[0.014; 0.347]
Samalin2014Sorafenib	1	54	0.019	[0.000; 0.099]
Srimuninnimit2014Efficacy	2	45	0.044	[0.005; 0.151]
Yamada2014Phase	5	13	0.385	[0.139; 0.684]
Random effects model		**2919**	**0.172**	**[0.140; 0.210]**
Heterogeneity: I–squared=78.7%, tau–squared=0.4885, p<0.0001				